Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Obesity 2015: Less Invasive Options Will Drive Growth In Market Hungry For Solutions

Executive Summary

Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.

You may also be interested in...



Bariatric Surgery Gets Formal Nod As Diabetes Treatment In Guidelines

Surgical procedures, including sleeve gastrectomy and laparoscopic adjustable gastric banding, have captured more attention as treatment options for type 2 diabetes. The first consensus clinical guidelines have now been published endorsing that approach for certain patients.

Ethicon Seeks To Expand Access To Bariatric Surgery, Increase Product Market Share Through Investment

With nearly 30 percent of the world’s population overweight or obese, Johnson & Johnson's Ethicon division is seeking to expand patients’ access to bariatric surgery in certain countries by funding studies that demonstrate its benefits.

Ethicon Seeks To Expand Access To Bariatric Surgery, Increase Product Market Share Through Investment

With nearly 30% of the world’s population overweight or obese, Johnson & Johnson's Ethicon division is seeking to expand patients’ access to bariatric surgery in certain countries by funding studies that demonstrate its benefits. By convincing payors in these countries that bariatric surgery addresses not only weight loss but also metabolic diseases, Ethicon hopes to increase its products' market share in these countries, too.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel